Suzhou Sunway Pharmaceutical

Suzhou Sunway Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the development of innovative therapies for metabolic disorders and oncology. The company's primary focus is on next-generation multi-target peptide agonists, with its lead candidate, SND002, currently in Phase 2 clinical trials for obesity and type 2 diabetes. Beyond its metabolic pipeline, which includes GLP-1/GIP dual agonists and GLP-1/GIP/GCGR tri-agonists, the company is also advancing small molecule programs for cancer treatment. Suzhou Sunway leverages its proprietary peptide engineering platform to optimize the pharmacological properties of its candidates, aiming to provide more effective and convenient treatment options for patients worldwide.